Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals
Reexamination Certificate
2008-01-01
2008-01-01
McKelvey, Terry (Department: 1655)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
C436S517000, C436S501000, C435S007100, C530S300000, C530S350000, C530S327000
Reexamination Certificate
active
09993366
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or the absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
REFERENCES:
patent: 5062935 (1991-11-01), Schlag et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: WO86/04144 (1986-07-01), None
patent: WO90/14148 (1990-11-01), None
patent: WO93/15198 (1993-08-01), None
patent: WO93/24834 (1993-12-01), None
patent: WO 98/07036 (1998-02-01), None
patent: WO98/07036 (1998-02-01), None
patent: WO 00/49410 (2000-08-01), None
patent: WO01/63294 (2001-08-01), None
patent: WO01/75454 (2001-10-01), None
Database EMBL “Online! WO9315198”, Database accession No. AAR39482, XP002233231 abstract.
Matilanienen, et al., “Early androgenetic alopecia as a marker of insulin resistance”, The Lancet (2000) vol. 356, No. 9256, pp. 1165-1166.
Merched, et al., “Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease”, Neuroscience Letters (1998) vol. 242, No. 2, pp. 117-119. XP-000863724.
Qin, et al., “Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation”, American Journal of Physiology: Heart and Circulatory Physiology (1998) vol. 43, No. 5, pp. 1836-1840-H1840.
Frishman, “Biologic Markers as Predictors of Cardiovascular Disease”, American Journal of Medicine (1998) vol. 104, No. 6A, pp. 18S-27S.
Takahashi et al., “Rapid and Sensitive Immunoassay for the Measurement of Serum S100β Using Isoform-specific Monoclonal Antibody”, Clinical Chemistry 45, No. 8, (1999) pp. 1307-1311.
Richter et al., “Composition of the peptide fraction in human blood plasma: database of circulating human peptides”, Journal of Chromatography B; 726 (1999) pp. 25-35.
Jackowski George
Marshall John
Davis Deborah A.
McHale & Slavin P.A.
McKelvey Terry
Nanogen Inc.
LandOfFree
Apolipoprotein biopolymer markers indicative of insulin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apolipoprotein biopolymer markers indicative of insulin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apolipoprotein biopolymer markers indicative of insulin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3921797